ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

NCT03595917 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

Interventions

DRUG: ABL001
DRUG: Dasatinib
DRUG: Prednisone
DRUG: Blinatumomab

Sponsor

Marlise Luskin, MD

Collaborators

[object Object]